# Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction

> **NCT01708889** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 43 (actual)

## Conditions studied

- Chronic Hepatitis B Virus Infection
- Chronic Hepatitis C Virus Infection

## Interventions

- **BIOLOGICAL:** BMS-914143 (Peginterferon Lambda-1a)

## Key facts

- **NCT ID:** NCT01708889
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01708889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01708889, "Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01708889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*